Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 8/20 | 1.00 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29551547 | 1.00 | TTR (1.00) | TTRGPR35ALDH1A1MAPTKDM4E | |
| SCHEMBL16450343 | 0.88 | TTR (0.78) | TTRGPR35ALDH1A1MAPTKDM4E | |
| SCHEMBL13121786 | 0.88 | TTR (0.78) | TTRGPR35ALDH1A1MAPTKDM4E | |
| SCHEMBL7373759 | 0.85 | TTR (0.74) | TTRGPR35ALDH1A1MAPTKDM4E | |
| SCHEMBL7369215 | 0.84 | TTR (0.73) | TTRGPR35ALDH1A1MAPTKDM4E | |
| SCHEMBL7369506 | 0.84 | TTR (0.73) | TTRGPR35ALDH1A1MAPTKDM4E | |
| SCHEMBL15159830 | 0.84 | TTR (0.73) | TTRGPR35ALDH1A1MAPTKDM4E | |
| SCHEMBL7366072 | 0.84 | TTR (0.73) | TTRGPR35ALDH1A1MAPTKDM4E | |
| SCHEMBL7428415 | 0.84 | TTR (0.72) | TTRGPR35ALDH1A1MAPTKDM4E | |
| SCHEMBL7370239 | 0.84 | TTR (0.72) | TTRGPR35ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003070082-A2 | ASSOCIATION OF SNPS IN THE COMT LOCUS AND NEIGHBORING LOCI WITH SCHIZOPHRENIA, BIPOLAR DISORDER, BREAST CANCER AND COLORECTAL CANCER | IDGENE PHARMACEUTICALS LTD. (IL) | 2003-08-28 | — | — | WO | claimed |
| EP-0444899-B1 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION YHTYMAE OY (FI) | 1997-02-05 | — | — | EP | claimed |
| US-5476875-A | Catechol derivatives | HOFFMAN-LA ROCHE INC. (US) | 1995-12-19 | — | — | US | claimed |
| US-5236952-A | Inhibit the enzyme catechol-O-methyltransferase; for treatment of Parkinson's disease administered with L-dopa | HOFFMANN-LA ROCHE INC. (US) | 1993-08-17 | — | — | US | claimed |
| EP-0237929-B1 | 3,5-DISUBSTITUTED PYROCATECHOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-06-02 | — | — | EP | claimed |
| EP-0444899-A2 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION-YHTYMÀ OY (FI) | 1991-09-04 | — | — | EP | claimed |
| EP-0237929-A1 | 3,5-Disubstituted pyrocatechol derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1987-09-23 | — | — | EP | claimed |
| US-11872236-B2 | Pharmacological agents for treating ocular diseases | CALASIA PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872236-B2 | Pharmacological agents for treating ocular diseases | CALASIA PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230105307-A1 | Identification of Stabilizers of Multimeric Proteins | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-04-06 | — | — | US | disclosed |
| US-11337935-B2 | Identification of stabilizers of multimeric proteins | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-05-24 | — | — | US | disclosed |
| US-20210154213-A1 | PHARMACOLOGICAL AGENTS FOR TREATING OCULAR DISEASES | CALASIA PHARMACEUTICALS INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20200016098-A1 | Identification of Stabilizers of Multimeric Proteins | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-01-16 | — | — | US | disclosed |
| EP-0444899-B1 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION YHTYMAE OY (FI) | 1997-02-05 | — | — | EP | disclosed |
| US-5476875-A | Catechol derivatives | HOFFMAN-LA ROCHE INC. (US) | 1995-12-19 | — | — | US | disclosed |
| US-5389653-A | Inhibitors of the enzyme catechol-O-methyltransferase; useful as co-medication in treatment of Parkinson's disease | HOFFMAN-LA ROCHE INC. (US) | 1995-02-14 | — | — | US | disclosed |
| US-5236952-A | Inhibit the enzyme catechol-O-methyltransferase; for treatment of Parkinson's disease administered with L-dopa | HOFFMANN-LA ROCHE INC. (US) | 1993-08-17 | — | — | US | disclosed |
| EP-0237929-B1 | 3,5-DISUBSTITUTED PYROCATECHOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-06-02 | — | — | EP | disclosed |
| EP-0444899-A2 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION-YHTYMÀ OY (FI) | 1991-09-04 | — | — | EP | disclosed |
| EP-0237929-A1 | 3,5-Disubstituted pyrocatechol derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230105307-A1 | Identification of Stabilizers of Multimeric Proteins | TTR, HSPBP1, HSPH1 | TTR 1/4885GPR35 3900/4885ALDH1A1 3493/4885 |
| US-11337935-B2 | Identification of stabilizers of multimeric proteins | TTR, HSPBP1, HSPH1 | TTR 1/4885GPR35 3900/4885ALDH1A1 3493/4885 |
| US-20210154213-A1 | PHARMACOLOGICAL AGENTS FOR TREATING OCULAR DISEASES | CRYAA, CRYAB, TTR | TTR 3/4885GPR35 897/4885ALDH1A1 1822/4885 |
| US-11872236-B2 | Pharmacological agents for treating ocular diseases | CRYAA, CRYAB, TTR | TTR 3/4885GPR35 897/4885ALDH1A1 1822/4885 |
| US-20200016098-A1 | Identification of Stabilizers of Multimeric Proteins | TTR, HSPBP1, HSPH1 | TTR 1/4885GPR35 3900/4885ALDH1A1 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.